Assessment of a causal relationship between body mass index and atopic dermatitis by Budu-Aggrey, Ashley et al.
                                                                    
University of Dundee
Assessment of a causal relationship between body mass index and atopic dermatitis
Budu-Aggrey, Ashley; Watkins, Sarah H.; Brumpton, Ben; Løset, Mari; Tyrrell, Jess; Modalsli,
Ellen H.
Published in:






Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Budu-Aggrey, A., Watkins, S. H., Brumpton, B., Løset, M., Tyrrell, J., Modalsli, E. H., Vie, G. Å., Palmer, T.,
Fritsche, L. G., Nielsen, J. B., Romundstad, P. R., Davey Smith, G., Åsvold, B. O., Paternoster, L., & Brown, S.
(2021). Assessment of a causal relationship between body mass index and atopic dermatitis. Journal of Allergy
and Clinical Immunology, 147(1), 400-403. https://doi.org/10.1016/j.jaci.2020.04.050
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. Jul. 2021
J ALLERGY CLIN IMMUNOL
JANUARY 2021
400 LETTERS TO THE EDITORChannel Research and TRP Research Platform Leuven (TRPLe), Department of
Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium; ethe Department
of Otorhinolaryngology, Academic Medical Center Amsterdam, Amsterdam, The
Netherlands; and fthe Laboratory of Upper Airways Research, Department of Otorhi-
nolaryngology, University of Ghent, Ghent, Belgium. E-mail: laura.vangerven@
uzleuven.be.
*These authors contributed equally to this work.
L.V.G. is supported by a TBM grant (project number 130240) of the Fund for Scientific
Research (FWO) Flanders, Belgium. P.W.H. is the recipient of a senior researcher
with a fellowship from the FWO (G076513N). B.S. is a postdoctoral fellow of the
FWO.
Disclosure of potential conflict of interest: The authors declare that they have no relevant
conflicts of interest.
REFERENCES
1. Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic
rhinitis: position paper of the European Academy of Allergy and Clinical
Immunology. Allergy 2017;72:1657-65.
2. Blom HM, Godthelp T, Fokkens WJ, KleinJan A, Mulder PG, Rijntjes E. The effect
of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in
the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis.
J Allergy Clin Immunol 1997;100(6 Pt 1):739-47.
3. Gevorgyan A, Segboer C, Gorissen R, van Drunen CM, Fokkens W. Capsaicin for
non-allergic rhinitis. Cochrane Database Syst Rev 2015;7:CD010591.
4. Van Rijswijk JB, Boeke EL, Keizer JM, Mulder PGH, Blom HM, Fokkens WJ.
Intranasal capsaicin reduces nasal hyperreactivity in idiopathic rhinitis: a
double-blind randomized application regimen study. Allergy 2003;58:754-61.
5. Baraniuk JN, Lundgren JD, Okayama M, Goff J, Mullol J, Merida M, et al.
Substance P and neurokinin A in human nasal mucosa. Am J Respir Cell Mol
Biol 1991;4:228-36.
6. Van Gerven L, Alpizar YA, Steelant B, Callebaut I, Kortekaas Krohn I, Wouters M,
et al. Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its
reversal by nasal capsaicin treatment. J Allergy Clin Immunol 2017;140:437-46.e2.
7. Van Gerven L, Alpizar YA, Wouters MM, Hox V, Hauben E, Jorissen M, et al.
Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential
cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with
idiopathic rhinitis. J Allergy Clin Immunol 2014;133:1332-9.e3.
8. Lacroix JS, Buvelot JM, Polla BS, Lundberg JM. Improvement of symptoms of
non-allergic chronic rhinitis by local treatment with capsaicin. Clin Exp Allergy
1991;21:595-600.
9. Lundblad L, Sipil€a P, Farstad T, Drozdziewicz D. Mometasone furoate nasal spray in
the treatment of perennial non-allergic rhinitis: a Nordic, multicenter, randomized,
double-blind, placebo-controlled study. Acta Otolaryngol (Stockh) 2001;121:505-9.
Available online May 19, 2020.
https://doi.org/10.1016/j.jaci.2020.04.054Assessment of a causal relationship
between body mass index and atopic
dermatitisTo the Editor:
Atopic dermatitis (AD) is an itchy, inflammatory skin
condition associated with multiple comorbidities. Observational
epidemiology suggests an increased prevalence of obesity in
patients with AD, but (1) whether there is a causal effect and
(2) whether obesity leads to AD or vice versa remain unclear.
Genetic predisposition to obesity has been shown to promote
psoriasis,1 but dermatologic disorders can also lead to reduced
participation in physical activity, resulting in weight gain. We
aimed to investigate evidence of causality in the association of
AD with elevated body mass index (BMI). 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY li-
cense (http://creativecommons.org/licenses/by/4.0/).We meta-analyzed 33 published studies examining the associ-
ation between obesity or elevated BMI and AD to summarize
available observational data (see Fig E1 in this article’s Online
Repository at www.jacionline.org). The odds ratio (OR) for AD
in overweight individuals was 1.05 (95% CI 5 0.94-1.19) in
adults (n 5 51,008) and 1.08 (95% CI 5 1.00-1.16) in children
(n 5 506,202) (see Fig E2 in this article’s Online Repository at
www.jacionline.org). For obese individuals, the OR for having
AD was 1.19 (95% CI 5 0.95-1.49) in adults (n 5 1,400,679)
and 1.20 (95% 5 CI 1.11-1.30) in children (n 5 796,514) (see
Fig E3 in this article’s Online Repository at www.jacionline.
org); the methods and results are detailed in the Methods and
Results sections of the Online Repository (at www.jacionline.
org). We extended the observational analysis by using 2 large
population-based studies from the United Kingdom and
Norway2,3 (for details, see the Online Repository and Tables
E1-E4). Among overweight individuals (BMI of 25-30 kg/m2),
the OR of AD was 1.02 per each 1-kg/m2 increase in BMI
(95%CI5 1.00-1.04;P5 .07; 4,820 cases and 130,776 controls);
a similar estimate was found among obese individuals (BMI >30
kg/m2) (ie, OR51.02 [95% CI5 1.01-1.03; P5 3.33 10–4] in a
sample of 2,741 cases and 73,907 controls) (see Fig E4 in this
article’s Online Repository at www.jacionline.org).
Observational epidemiology has several limitations, including
bias from confounding and reverse causation; this restricts its
utility for causal inference. However, causality and the direction
of effect can be investigated by mendelian randomization (MR).
MR uses genetic variants as a proxy for the exposure (eg,BMI) to
estimate the effect on an outcome (eg, AD). Genetic variants are
randomly allocated at fertilization, therefore avoiding
confounding; they are not affected by outcomes later in life,
thus avoiding reverse causation. Genome-wide association
studies (GWASs) have identified single-nucleotide
polymorphisms (SNPs) associated with BMI (<_941 loci4,5) and
AD (24 loci in European populations6). These SNPs can be
combined into a genetic risk score (GRS) or ‘‘genetic instrument’’
that acts as a proxy for the specified trait during MR.
We conducted MR analysis by using data from the largest
population-based studies in the United Kingdom (UK Biobank2)
and Norway (Nord-Trøndelag Health Study, Norway3 [HUNT,
2006-08]) along with the largest published GWASs for BMI4,5
and AD6 to date, representing a total of 742,611 individuals
(see Table E5 in this article’s Online Repository at www.
jacionline.org). One-sample MR was performed in the UK
Biobank and HUNT data sets with the individuals’ BMI SNPs,
measured BMI, and AD status. Two-sample MR using published
GWAS data4-6 was performed and meta-analyzed with the
1-sample estimate to obtain an overall causal estimate. Similarly,
reverse MRwas conducted to investigate the effect of AD genetic
risk on BMI. Methodologic details and sensitivity analysis are
described in the Online Repository, including Fig E5.
The BMI GRS was strongly associated with BMI in both the
UK Biobank and HUNT data sets (see Figs E6 and E7 in this
article’s Online Repository at www.jacionline.org), supporting
its use as a genetic instrument. Potential confounders of the
GRS-BMI association were detected (see Figs E6-E9), but the
magnitudes were minimal in comparison with the strength of
association with BMI. Similarly, the AD GRS was a good
predictor of AD in both the UK Biobank (OR 5 1.26 [95%
CI 5 1.23-1.28]; F-statistic 5 2036; R2 5 0.7%) and
HUNT (OR 5 1.15 [95% CI 5 1.11-1.21]; F-statistic 5 97;
FIG 1. MR analysis of the causal effect of BMI on AD. Meta-analysis of 1-sample and 2-sample MR estimates
using individual BMI SNPs as instruments. Estimates are given per 1-kg/m2 increase in BMI.
FIG 2. Reverse direction MR analysis: effect of AD genetic risk on BMI. Meta-analysis of 1-sample and
2-sample MR estimates using individual AD SNPs as instrumental variables. Estimates represent change in
BMI (kg/m2) per doubling odds of AD.
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(R501X/rs61816761), which is known to show strong association
with AD.
Meta-analyzed 1- and 2-sample MRs show evidence of a small
causal effect of higher BMI increasing the risk of AD (OR5 1.02
[95% CI 5 1.00-1.04]; P 5 .03) (Fig 1). This represents an
increase in AD risk by approximately 2% for each 1-kg/m2
increase in BMI, which is remarkably similar to the observational
estimate (see Figs E2 and E3 in the Online Repository).
Importantly, sensitivity analyses showed little evidence of
pleiotropy (for details, see the Sensitivity Analysis section,
Table E6, Fig E10, and Fig E11 in this article’s Online Repository
at www.jacionline.org) or heterogeneity among the individual
SNP effect estimates (UK Biobank Q 5 101.07 [P 5 .32];
HUNT Q 5 100.04 [P 5 .37]). Two-sample MR using the larger
number of recently published BMI SNP estimates (941 SNPs)4
gave similar evidence of a causal effect on AD risk (OR 5 1.08
[95% CI 5 1.01-1.16]; P 5.02).
In the reverse direction, meta-analysis gave weak evidence of a
very small causal effect (Fig 2): a 0.03-kg/m2 change in BMI per
doubling odds of AD (95% CI 5 –0.02 to 0.08; P 5 .24). There
was little evidence of pleiotropy but modest heterogeneity among
the individual SNP effects (see Fig E12 and Table E7 in in this
article’s Online Repository at www.jacionline.org). The
difference in BMI between patients with AD and controlsestimated in 1-sample MR (0.15 kg/m2, 95% CI -1.97 to 2.27)
was small compared with observational estimates (see
Tables E1 and E2), indicating that the association is mainly
explained by the causal effect of BMI on AD.
The association of obesity with cardiometabolic disease and
systemic inflammation is now well recognized, and clinical
guidelines recommend screening patients with psoriasis for
obesity. The presence of a causal effect and the direction of effect
are both clinically relevant, to define a primary target (ie, obesity)
for intervention. Our MR analysis shows evidence that higher
BMI increases the risk of AD (ie, a 2% increase in disease risk
for each 1-kg/m2 increase in BMI). Conversely, there was no
strong evidence of a causal effect of AD genetic risk on BMI;
the estimate of 0.03 kg/m2 suggests that genetic risk for AD has
little meaningful influence on an individual’s BMI. These
findings may be compared with the causal effect of BMI on
psoriasis and lack of effect of psoriasis genetic risk on BMI.1
The effect of BMI on AD is more modest than the effect size
observed in psoriasis, but the high prevalence of obesity
(in more than one-third of US adults) and AD (in <_10% of adults)
demonstrate the potential importance of this causal effect on a
population scale.
The molecular mechanisms by which obesity contributes to
skin inflammation remain unclear. Excess adipose tissue
secretes proinflammatory cytokines and hormones,7 and atopic
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barrier in obese individuals.8 Changes in the adipocytes and
lymphatic vessels may also contribute to obesity-related skin
inflammation.8 Research to define mechanisms underlying the
causal relationship demonstrated by MR may identify novel
therapeutic targets.
Our MR analyses have various strengths as well as weaknesses.
The large sample size is powerful, and the genetic instruments are
strong. The 2-sample analysis included an overlap of data sources
(from the HUNT study), which has the potential to bias the causal
estimate, but this bias would be in the direction of the null. There is
the possibility of misclassification of AD, and because AD often
shows remission in childhood, this phenotype may be particularly
susceptible to recall bias in adult studies; however, thiswould likely
drive any estimate toward the null. It is also important to note that
the MR methodology applied here does not define temporal
relationship. Genetic risk has a lifetime effect and therefore
predates disease onset, but a causal effect determined by MR
does not rely on obesity occurring before the onset of AD.
However, when we attempted to mitigate this issue by repeating
the MR analyses using SNPs that are strongly associated with
childhood BMI,9 a causal estimatewith the same direction of effect
was obtained (OR 5 1.04; 95% CI 5 1.01-1.07; P 5 .01).
Nevertheless, replication of these analyses within pediatric cohorts
with large sample sizes would be valuable future work.
In conclusion, we have found evidence of a small but
potentially important causal effect of BMI on AD. Clinical trials
have shown that interventions to promote weight loss can lead to
improvement in psoriasis, but this approach has not been tested in
AD. The results of our study provide support for the investigation
of obesity management strategies and/or targeting of the
adipocyte-keratinocyte cross-talk as therapeutic opportunities
for AD. This may contribute to the prevention of AD, as well as
to a reduction in the population prevalence of this chronic disease.
This research was conducted by using data from the UK Biobank Resource
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cin, teicoplanin, and telavancin in
patients with HLA-A*32:01–positive
vancomycin-induced DRESS sharing
an HLA class II haplotypeTo the Editor:
Vancomycin is a glycopeptide antibiotic used to treat resistant
gram-positive infections. It is associated with a life-threatening,
delayed T-cell–mediated reaction, drug reactionwith eosinophilia
and systemic symptoms (DRESS) presenting with fever, rash,
hematologic abnormalities, lymphadenopathy, and organ
involvement that occurs 2 to 6 weeks after initiation of
vancomycin treatment.1 We demonstrated that HLA-A*32:01 is
strongly associated with vancomycin-induced DRESS in
European populations.2 All glycopeptide antibiotics contain a
heptapeptide core structure, and cross-reactivity should be
considered when treating patients who have had a previous
hypersensitivity reaction to vancomycin (see Fig E1 in this
article’s Online Repository at www.jacionline.org).3 Cross-
reactivity remains controversial, as some patients presenting
with teicoplanin-induced DRESS showed subsequent tolerability
to vancomycin4-7 and patients with teicoplanin-induced DRESS
confirmed by a positive intradermal skin test result had a negative
result of a skin test to vancomycin.8
To examine the immunologic cross-reactivity among 4
glycopeptide antibiotics (ie, vancomycin, teicoplanin,
dalbavancin, and telavancin), adults who were at least 18 years
old with a probable diagnosis of vancomycin-induced DRESS
defined as having a corresponding Naranjo adverse drug
reaction score of 5 or higher (probable adverse drug reaction),
having a Registry of Severe Cutaneous Adverse Reactions score
of 4 or higher (probable DRESS), and carrying HLA-A*32:01
(the recently described risk allele for vancomycin-induced
DRESS) were recruited between January 2010 and September
2019 through drug allergy clinics and inpatient facilities at
participating institutions (Vanderbilt University Medical Center
in Nashville, Tennessee, and Austin Health, Peter MacCallum
Cancer Centre, Fiona Stanley Hospital and Royal Perth Hospital
in Perth, Western Australia, Australia). All patients provided
informed consent for collection of saliva and blood to be stored
as DNA and PBMCs.IFN-g release in response to overnight incubation with
implicated drugs was performed by ELISpot assay (3420-2H;
Mabtech, Stockholm, Sweden) in triplicate from thawed PBMCs
(rested overnight) and included negative (unstimulated) and
positive (anti-CD3 Mabtech antibody, staphylococcal
enterotoxin B, and/or cytomegalovirus pp65) controls. Control
PBMCs from glycopeptide unexposed HLA-A*32:01–positive
andHLA-A*32:01–negative individuals were also used. PBMCs
plated at 200,000 cells per well were incubated with
vancomycin, teicoplanin, dalbavancin, telavancin, and other
implicated drugs at concentrations representative of maximum
serum concentrations, as well as those 10-fold higher and
10-fold lower (Fig 1). A positive response was defined as more
than 50 spot-forming units per million cells after background
removal as per previous the definitions.9 High-resolution
4-digit HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DR, and
HLA-DQ typing was performed by using sequence-based typing
with previously published protocols.2
A total of 15 patients who met the clinical inclusion criteria for
vancomycin-induced DRESS syndrome were enrolled into this
study. Their demographics, clinical characteristics, and DRESS
history are described in Table E1 (in this article’s Online
Repository at www.jacionline.org), and full HLA typing of all
patients is described in Table E2 (in this article’s Online
Repository at www.jacionline.org).
All patients with vancomycin-induced DRESS exhibited a
dose-dependent positive IFN-g ELISpot response to vancomycin
(Fig 1 and see Table E3 in this article’s Online Repository at
www.jacionline.org); all had a clear negative response to both
concentrations of dalbavancin (Fig 1). Three patients overall
showed cross-reactivity, with all 3 showing a positive response
to telavancin and 2 of them also demonstrating a positive IFN-g
ELISpot response to teicoplanin. One of the 2 patients who had
positive IFN-g ELISpot responses to vancomycin, teicoplanin,
and telavancin (patient 15 and see Table E3) was intradermally
skin-tested to both vancomycin and teicoplanin and showed
positive responses to both (see Fig E2 in this article’s Online
Repository at www.jacionline.org), which was not seen in
glycopeptide-unexposed controls (n5 5) and 3 patients (patients
9, 10, and 11) with HLA-A*32:01–positive vancomycin-induced
DRESS who showed positive delayed intradermal testing and
IFN-g ELISpot results to vancomycin but negative IFN-g
ELISpot and intradermal testing results to teicoplanin. Patients
1, 3, and 5 also tolerated ingestion challenges with medications
concurrently administered at the time of vancomycin-induced
DRESS.
In samples with sufficient cell numbers, PBMCs were tested
against other concurrently administered medications potentially
implicated in DRESS development (see Fig E3 in this article’s
Online Repository at www.jacionline.org). IFN-g ELISpot was
also performed on PBMCs from non–HLA-matched healthy
donors (n 5 5) and a HLA-A*32:01–positive vancomycin naive
control (n 5 1), with all exhibiting a negative response to all 4
drugs (data not shown).
Vancomycin is implicated in up to 40% of patients with
antibiotic-related DRESS.1 The prevalence of vancomycin-
induced DRESS appears to be increasing, and it is the second
most common cause of DRESS overall reported to the US Food
and Drug Administgration Adverse Event Reporting System be-
tween 1999 and 2019 (https://open.fda.gov/data/faers/ [accessed
March 2, 2020]). HLA-A*32:01 has recently been reported as a
